Fibroblast Activation Protein-Directed Imaging Outperforms ¹⁸F-FDG PET/CT in Malignant Mesothelioma: A Prospective, Single-Center, Observational Trial

Lukas Kessler, Felix Schwaning, Martin Metzenmacher, Kim Pabst, Jens Siveke, Marija Trajkovic-Arsic, Benedikt Schaarschmidt, Marcel Wiesweg, Clemens Aigner, Till Plönes, Kaid Darwiche, Servet Bölükbas, Martin Stuschke, Lale Umutlu, Michael Nader, Dirk Theegarten, Rainer Hamacher, Wilfried E.E. Eberhardt, Martin Schuler, Ken HerrmannWolfgang P. Fendler, Hubertus Hautzel

German Cancer Research Center
University Hospital of Essen
Medical University of Vienna
Universitätsklinikum Carl Gustav Carus Dresden

Publikation: Beitrag in Fachzeitschrift › Artikel › Begutachtung

1 Zitat (Scopus)

sortieren
Gewicht:
Alphabetisch

Fibroblast Activation Protein-Directed Imaging Outperforms ¹⁸F-FDG PET/CT in Malignant Mesothelioma: A Prospective, Single-Center, Observational Trial

Fingerprint

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Fibroblast Activation Protein-Directed Imaging Outperforms 18F-FDG PET/CT in Malignant Mesothelioma: A Prospective, Single-Center, Observational Trial

Fingerprint

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Fibroblast Activation Protein-Directed Imaging Outperforms ¹⁸F-FDG PET/CT in Malignant Mesothelioma: A Prospective, Single-Center, Observational Trial